Tag Archives: and-the

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Posted: January 14, 2024 at 2:35 am

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase 2 (AMPLIFY-7P) study of ELI-002 7P as an adjuvant monotherapy in KRAS mutated pancreatic ductal adenocarcinoma (“PDAC”).

Excerpt from:
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Posted in Global News Feed | Comments Off on Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

AI and the safe travel lane of diabetes care – Central Michigan University

Posted: January 14, 2024 at 2:34 am

AI and the safe travel lane of diabetes care  Central Michigan University

More:
AI and the safe travel lane of diabetes care - Central Michigan University

Posted in Diabetes | Comments Off on AI and the safe travel lane of diabetes care – Central Michigan University

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Posted: January 6, 2024 at 2:37 am

If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea

Read this article:
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Posted in Global News Feed | Comments Off on Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea